Response Comment on “In Silico Comparison of Separate or Combinatorial Effects of Potential Inhibitors of the SARS-CoV-2 Binding Site of ACE2”

Dear Editor-in-Chief

Thank you for the authors’ comments. The overall point of view in the related text is acceptable but it should be considered that we did not use herbal compounds as angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs). Our suggested compounds are potential inhibitors of the SARS-CoV-2 binding site of ACE2 without interference with active site of the enzyme.

In other words, inhibition of ACE2 will compromise the condition because it is involved in other important substrate conversion (1) and who has more active ACE2 shows less symptoms, like children.